nCoV: Serological detection of past SARS-CoV-2 infection by non-invasive sampling for field epidemiology and quantitative antibody detection

Lead Research Organisation: Imperial College London


Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.


10 25 50
publication icon
Tedder RS (2021) Appropriate selection of convalescent plasma donors for COVID-19. in The Lancet. Infectious diseases

publication icon
Garson JA (2022) Highly sensitive and specific detection of the SARS-CoV-2 Delta variant by double-mismatch allele-specific real time reverse transcription PCR. in Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology

publication icon
Turner-Stokes T (2021) Serologic Screening for Coronavirus Disease 2019 in Patients With Glomerular Disease. in Kidney international reports

Description The present invention is directed to a method for detecting the presence or absence of SARS-Cov-2 antibodies in a sample, the method comprising: a. contacting the sample with a solid-phase support having a fusion protein immobilised thereto, said fusion protein comprising a first antigen and a scaffold polypeptide, 1. wherein the first antigen is a SARS-Cov-2 receptor binding domain polypeptide that binds anti-SARS-Cov-2 antibody, and ii. wherein the scaffold polypeptide immobilises the fusion protein to the solid-phase support and presents the first antigen away from the solid-phase support; b. allowing SARS-Cov-2 antibodies present in the sample to bind to the first antigen, thereby forming a complex of first antigen and SARS-Cov-2 antibody; c. contacting said complex with a labelled second antigen, wherein said labelled second antigen comprises a SARS-Cov-2 receptor binding domain polypeptide that binds SARS-Cov-2 antibody; d. allowing said labelled second antigen to bind to SARS-Cov-2 antibody present in the sample; e. removing labelled second antigen that is not bound to said complex; and f. detecting the presence of labelled second antigen bound to said complex; wherein the presence of labelled complex indicates the presence of SARS-Cov-2 antibody in the sample, and wherein the absence of labelled complex indicates the absence of SARS-Cov-2 antibody in the sample. 
IP Reference WO2022013574 
Protection Patent application published
Year Protection Granted 2022
Licensed No
Impact highest specificity and sensitivity, also predicts and measures neutralising antibody